Biocon’s arm secures approval for Tacrolimus capsule from NMPA

03 Jan 2025 Evaluate

Biocon’s wholly owned subsidiary -- Biocon Pharma has received approval for Tacrolimus capsule in 0.5mg, 1mg and 5mg strengths, from the National Medical Products Administration (NMPA), China. 

Tacrolimus is an immunosuppressant used in the treatment of organ transplant patients, which reduces the body’s ability to reject a transplanted organ. The approval further adds to Biocon’s portfolio of complex drug products and will be commercialised in the region expeditiously.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.


Biocon Share Price

323.85 5.05 (1.58%)
30-Apr-2025 13:57 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1825.00
Dr. Reddys Lab 1181.10
Cipla 1550.25
Lupin 2101.80
Zydus Lifesciences 889.90
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...